CombiCare Safety of multimodality treatment with a combination of intraoperative Chemotherapy and surgical Resection in locally confined or borderline resectable pancreatic cancer (Aktiv)
DISPACT-2 Distal Pancreatectomy – A randomised controlled trial to compare minimal-invasive distal pancreatectomy to open resection (DISPACT-2 Trial) (Aktiv)
Erstlinie
COMPETE Eine prospektive, randomisierte, kontrollierte, offene, multizentrische Phase III Studie zur Beurteilung der Wirksamkeit und Sicherheit der Peptid-Rezeptor-Radionuklid-Therapie (PRRT) mit 177Lutetium-Edotreotid im Vergleich zur gezielten molekularen Therapie mit Everolimus bei Patienten mit inoperablen, progressiven, Somatostatin-Rezeptor positiven (SSTR +), neuroendokrinen Tumoren des Magen-Darm Trakts oder pankreatischen Ursprungs (GEP-NET) (Aktiv)
FGCL-3019-087 Eine randomisierte, doppelblinde Phase-3-Studie mit Pamrevlumab oder Placebo in Kombination mit Gemcitabin Plus Nab-Paclitaxel oder FOLFIRINOX als neoadjuvante Behandlung bei Patienten mit lokal fortgeschrittenem, inoperablem Bauchspeicheldrüsenkrebs (Aktiv)
FOOTPATH First-line Therapy in Metastatic PDAC (Aktiv)
HOLIPANIC Open-label, Single Arm Phase II Trial Investigating the Efficacy, Safety and Quality of Life of Neoadjuvant Chemotherapy With Liposomal Irinotecan Combined With Oxaliplatin and 5-Fluorouracil/Folinic Acid Followed by Curative Surgical Resection in Patients With Hepatic Oligometastatic Adenocarcinoma of the Pancreas (Aktiv)
NEOPA Sequential Neoadjuvant Chemoradiotherapy (CRT) Followed by Curative Surgery vs. Primary Surgery Alone for Resectable, Non-metastasized Pancreatic Adenocarcinoma (Aktiv)
Neonax_AIO-PAK-0313 Neoadjuvant plus adjuvant or only adjuvant nab-paclitaxel plus gemcitabine for resectable pancreatic cancer (Aktiv)
PACK Pancreatic Cancer and Carbon Ion Radiotherapy (Aktiv)
Zweitlinie oder später
025/05 Gemcitabin/Cisplatin in Kombination mit Hyperthermie für Patienten mit Pankreaskarzinom (Aktiv)
BI 1403-0011 - BRIGHTLINE-2 Brightline-2: A Phase IIa/IIb, Open-label, Single-arm, Multi-centre Trial of Brigimadlin (BI 907828) for Treatment of Patients With Locally Advanced / Metastatic, MDM2 Amplified, TP53 Wild-type Biliary Tract Adenocarcinoma, Pancreatic Ductal Adenocarcinoma, or Other Selected Solid Tumours (Aktiv)
CNIR178X2201 Study of efficacy and safety of NIR178 and PDR001 combination in patients with selected solid tumors and non-Hodgkin lymphoma (Aktiv)
MCLA-128-CL01/MERUS A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion (Aktiv)
SEPION AX-8619 Determination Safety and Tolerability of Epigenetic and Immunomodulating Drugs in Combination With Chemotherapeutics in Patients Suffering From Advanced Pancreatic Cancer (Aktiv)